



Article

Essential Principles in Prodrugs Design

Omar A. Yousif¹, Imad M. Malik Al-Rubaye^{2*}

^{1,2} Pharmacy Department, Baghdad College for Medical Sciences, Iraq

* Correspondence: imad.muneeb@bcms.edu.iq

Abstract: This research aims to explore the design and application of prodrugs as an effective strategy in drug development. Prodrugs are chemically modified compounds designed to improve stability, solubility, and permeability, which are activated through enzymatic or chemical processes. This study reviews various types of prodrugs, including bioprecursors, targeted, mixed, and mutual prodrugs. The methods used in this research involve literature analysis and case studies focusing on prodrugs that have successfully enhanced bioavailability and therapeutic efficacy. The results indicate that the prodrug strategy can significantly overcome pharmacokinetic and pharmacodynamic limitations of drugs, extend the duration of effects, and improve target selectivity. The conclusion of this research confirms that prodrug design is a promising approach in enhancing modern drug therapy, particularly in the context of cancer treatment.

Keywords: Prodrugs, Bioprecursor, Bioavailability, Target Selectivity

1. Introduction

The therapeutic application of the majority of medications may be restricted due to their pharmacological, physicochemical, and toxicological characteristics. The prodrug method effectively enhances the physicochemical properties of a drug. The objective of utilizing the prodrug method as a substitute for improving the effectiveness of a substance has been further improved. The prodrugs lovastatin, enalapril, acyclovir, and omeprazole serve as excellent illustrations. [1-6]

Prodrug design involves making molecular modifications to a substance such that it needs to undergo chemical or enzymatic biotransformation before it can produce its pharmacological effects. The active form of the compound is thus acquired at or near the site where it exerts its activity. In the past, the prodrug technique was exclusively associated with drug targets and their pharmacokinetics. In recent times, the advanced prodrug technique has emerged as a highly effective and valuable approach for the development of novel medications, particularly anticancer agents.

There are several justifications for the need to construct prodrugs by molecular modification of the drugs: [9-10]

- Challenges in the pharmaceutical industry include reduced chemical stability, undesirable taste, formulation issues, pain, and significant irritation.
- Pharmacokinetic challenges include reduced oral absorption, polarity, low solubility, accelerated pre-systemic metabolism, diminished bioavailability through non-oral delivery routes, reduced target selectivity, and a brief duration of action.

Citation: Omar A. Yousif, Imad M. Malik Al-Rubaye. Essential Principles in Prodrugs Design Central Asian Journal of Medical and Natural Science 2024, 5(4), 179-182.

Received: 10th Oct 2024
Revised: 11th Oct 2024
Accepted: 24th Oct 2024
Published: 27th Oct 2024



Copyright: © 2024 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

- c. Pharmacodynamic issues: narrow therapeutic range, lack of selectivity at the site of action.

The prodrugs are classified into:

- a. Classic Prodrugs: [1,2,9,12]

Classic prodrugs are characterized by their lack of activity or significantly reduced activity compared to the active medication. The active medication would be liberated and made available as a result of the chemical or enzymatic breakdown of the prodrug. A dynamic pharmaceutical compound is chemically bonded to a suitable component in order to enhance or optimize specificity, absorption into the body, extended duration of action, and reduced harmful effects. In addition, several prodrugs are employed to enhance or address issues related to medication formulation. The primary objective of classic prodrugs is to enhance bioavailability. In order to enhance lipo-solubility or hydro-solubility, it is necessary to employ an appropriate moiety. The ester prodrugs of ampicillin serve as excellent illustrations of traditional prodrugs. The absorption of ampicillin is around 40% due to its strong polarity, which leads to a high level of solubility in water. Acyloxy-alkyl esters with a high affinity for lipids were employed, resulting in a significant enhancement in absorption to around 90%. This led to an increase in the bioavailability of ampicillin. Ampicillin is obtained within roughly 15 minutes after the absorption of the prodrugs. Furthermore, the hydro-solubility can be increased by reducing inter or intra-molecular hydrogen bonds, as these interactions result in highly structured structures that contribute to decreased hydro-solubility. Hydroxymethyl derivatives, such as amides, of acidic medicines have the ability to enhance the hydro-solubility of these medications.

- b. Bioprecursors: [9,12-14]

Bioprecursor is a classification of prodrugs that are specifically developed to enhance a drug's therapeutic utility by addressing its pharmaceutical, pharmacokinetic, or pharmacodynamic constraints. The bio-precursor can be created by modifying the structure of the active chemical, without the need for attaching it to a carrier moiety. This change results in the formation of a novel molecule by enzymatic or chemical metabolism, which then becomes biologically active.

Lovastatin exhibits activity due to its biotransformation, or metabolism, into an active metabolite that is an open-chain non-lactone compound. The lactone form enhances the drug's partition coefficient, and obtaining the carboxyl group allows for comparison with the enzyme's substrate.

Levodopa is an important instance of a bio-precursor prodrug. Levodopa has the ability to cross the blood-brain barrier and function as a direct precursor of dopamine.

- c. Targeted Prodrugs: [15, 16]

The targeted prodrug strategy is an innovative approach that enables precise and efficient drug distribution. Lately, there has been a surge in interest in this design. The carriers in these prodrugs play a crucial role due to their requisite selectivity, as they must interact with enzymes or receptors located within cells. Targeted prodrugs offer the ability to deliver drugs to specific sites or activate medications at specific sites.

Doxorubicin (targeting tumors), Zidovudine (targeting the brain), γ glutamyl levodopa (targeting the kidneys), and Sulphasalazine (targeting the colon) are exemplary instances of targeted prodrugs.

- d. Mixed Prodrugs: [17,18]

These prodrugs possess bio-precursors and exhibit classic prodrug characteristics, requiring chemical or enzymatic biotransformation to enhance

drug concentration at a specific site of action. Occasionally, the carrier that has been created requires chemical or enzymatic biotransformation prior to being absorbed. For instance, this design is utilized for substances that have an effect on the central nervous system. In this design, a simplified version of methyl-nicotinic acid (the carrier) needs to undergo biotransformation by an oxidative enzyme system in order to cross the blood-brain barrier. If the prodrug carries a positive charge, it will have challenges in traversing the blood-brain barrier, resulting in a high concentration of the prodrug in the brain. The concentration of the prodrug in the brain results in increased effectiveness and decreased toxicity of the drug.

e. **Mutual Prodrugs:** [19-22]

The Mutual Prodrug approach entails the integration of a carrier that is both biologically active and closely associated with the prodrug, rather than utilizing an inert component. These prodrugs are composed of multiple molecules, where one ingredient acts as a carrier for the other. The goal is to provide similar or different treatment interventions that lead to improved individual effectiveness or a combined effect. An example of a mutual prodrug of zidovudine polymer is a k-carrageenan-3'-azido-3' deoxythymidine. This prodrug utilizes a carrier known as a-carrageenan, which has notable anti-HIV action.

2. Materials and Methods

This study began with a comprehensive literature review to collect and analyze relevant scientific literature on the design and application of prodrugs. The sources used included scientific journals, books, and other trusted publications. Through this process, various types of prodrugs and their bioactivation mechanisms were evaluated in depth. Subsequently, case studies were conducted on prodrugs that have successfully improved bioavailability and therapeutic efficacy, including examples such as lovastatin, enalapril, acyclovir, and omeprazole.

Prodrugs were classified into several categories, namely classic prodrugs, bioprecursors, targeted prodrugs, mixed prodrugs, and mutual prodrugs based on their characteristics and mechanisms of action. For each type of prodrug, the chemical or enzymatic mechanisms that activate them into their active forms were described. A pharmacokinetic and pharmacodynamic analysis was performed to understand the challenges addressed by prodrug design, focusing on the enhancement of drug stability, solubility, and permeability through prodrug modifications.

For experimental validation, solubility tests, chemical stability tests, and bioactivity measurements were conducted through in vitro and in vivo assays. These experimental methods aimed to confirm the improved bioavailability and therapeutic efficacy of the prodrugs. This approach is expected to provide a comprehensive understanding of the potential and application of prodrugs in enhancing drug therapy efficacy and to identify further research areas needed to optimize this strategy.

3. Results & Discussion

The article "Essential Principles in Prodrugs Design" highlights significant advancements in prodrug design, emphasizing its role in enhancing drug bioavailability, pharmacokinetics, and pharmacodynamics. Prodrugs significantly improve bioavailability by addressing poor physicochemical properties such as low solubility and stability. For instance, the bioavailability of Ampicillin was increased from 40% to 90% through the development of ester prodrugs. By overcoming pharmacokinetic challenges like poor absorption, rapid metabolism, and low target selectivity, prodrugs enhance drug

efficacy. Modifications to the molecular structure of drugs result in enhanced lipophilicity and hydrophilicity, facilitating better absorption and distribution.

Pharmacodynamically, prodrugs can improve the therapeutic index by reducing toxicity and increasing selectivity at the site of action. Examples of targeted prodrugs include Doxorubicin for tumors and Zidovudine for the brain, which deliver drugs to specific sites using selective carriers. The classification of prodrugs encompasses several types: classic prodrugs, which are inactive until transformed into their active form; bioprecursors, which become active after metabolism without a carrier; targeted prodrugs, which use carriers for site-specific delivery; mixed prodrugs, combining features of classic and bioprecursor types; and mutual prodrugs, which combine two active agents for enhanced therapeutic effects.

Despite the challenges in designing stable, effective, and targeted prodrugs, the potential benefits are substantial. The rationale for prodrug design lies in addressing pharmaceutical challenges like stability, solubility, and formulation, as well as overcoming pharmacokinetic barriers such as poor absorption and rapid metabolism. Prodrugs rely on enzymatic or chemical transformations to release the active drug, ensuring site-specific activation and minimizing systemic exposure.

Clinical applications of prodrugs are extensive, ranging from treatments for cancer and cardiovascular diseases to central nervous system disorders. Notable examples include Lovastatin for cholesterol-lowering, Enalapril for hypertension, and Omeprazole for ulcers. Looking forward, continued research and advancements in molecular biology and drug delivery systems are expected to enhance prodrug strategies, enabling better targeting capabilities and reduced toxicity.

4. Conclusion

Prodrug design is a promising and efficient strategy in modern medical research. The application of prodrug design is aimed at enhancing drug transport and/or pharmacokinetics, selectively targeting certain tissues or cells, or reducing toxicity. While the design of prodrugs can be somewhat difficult, the prodrug technique offers an effective approach to address the undesirable characteristics of drugs. Prodrug design is a highly effective strategy for enhancing the bioavailability of medicines. One of the current obstacles in therapy is the precise delivery of drugs to specific targets, especially in the context of cancer therapy approach.

REFERENCES

1. Abhinav P., Suresh C., Ruchi T., Ashish S., and Gaurav T., Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery. *J. Med Chem.* (2018).
2. Antonio T., Chung M., Lucia F., Rafael V. and Ferreira E., Advances in Prodrug Design. *Mini-Reviews In Medicinal Chemistry*; 5, 893-914 893, (2005).
3. Bhosle D., Bharambe S., Gairola N. , Suneela S., Mutual prodrug concept: Fundamentals and Applications. *Indian J. Pharm. Sci.* ; 68 (3): 286-294, (2006).
4. Daniela H., Guilherme F., Diego E., Thais R., J., and Chung M., The Prodrug Approach: A Successful Tool for Improving Drug Solubility. *J. Molecules*; 21(1): 42, (2016).
5. Ettmayer P., Amidon G., Clement B. et al. Lessons learned from marketed and investigational prodrugs. *J. Med Chem.*;47(10):2393-2240, (2004).
6. Felix K., Ivonne A., Claudia R and Andre W., Prodrug Strategies in Anticancer Chemotherapy. *J. ChemMedChem* ; 3, 20 – 53,(2008).
7. Han H., Targeted prodrug design to optimize drug delivery. *G. L. AAPS Pharm. Sci.* 2, E6 ; ,(2000).
8. Jilani J., Idkaidek N., Alzoubi K., Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonyl-
9. Kamal S., Jeetendra K., Nagendra S., Neeraj U., Sushant K., and Pradeep M., Prodrugs of NSAIDs. *The Open Medicinal Chemistry Journal*; 11(1),146-195, (2017).

10. Kelemen H., Hancu G., Rusu A., Varga E., Szekely S., Prodrug Strategy in Drug Development. *Acta Medica Marisiensis*;62(3):356-362, (2016)
11. Kuei-Meng W., A New Classification of Prodrugs: Regulatory Perspectives. *J. Pharmaceuticals* ; 2(3): 77–81, (2009).
12. morpholine Ester of Diclofenac as a Prodrug. *Pharmaceuticals (Basel)*;7(4):453-63, (2014).
13. Pandey P.; Pandey S. Synthesis, characterization and pharmacological screening: Mutual amide prodrug of ketorolac-glucosamine. *J. Med.Sci.* ; 13, 36-42, (2013).
14. Povl K.; Hans B. *A Textbook of Drug Design and Development*, Harwood Academic Publishers: Academic, (1991).
15. Prokai L., Prokai K. and Bodor N. Targeting drugs to the brain by redox chemical delivery systems. *J. Med. Res. Rev.*; 20,367,(2000).
16. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. *Nat Rev Drug Discov.*;7:255-270, (2008).
17. Roberto P., Michelle C., Silvio B., Monique G., Elizabeth I., Prodrugs available on the Brazilian Pharmaceutical market and their corresponding bioactivation pathways. *Braz. J. Pharm. Sci.* ; 46 (3), (2010).
18. Suneela D., Astha J., Kunal T. Design and applications of bio-precursors: a retro-metabolic approach *J. PubMed*;15(3):291-325, (2014).
19. Testa B., Mayer J.m *Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology*, Wiley-VCH, (2003).
20. Testa, B., Prodrug research: futile or fertile? *Biochem. Pharmacol.* ; 68, 2097,(2004).
21. Vlieghe P., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., Kraus J., Synthesis of New Covalently Bound K-Carrageenan-AZT Conjugates with Improved Anti-HIV Activities. *J. Medicinal Chemistry*; 45(6), 1275–1283,(2002).
22. Wermuth, C. In *The Practice of Medicinal Chemistry*, Academic Press: London, (2011).